Recombinant Mouse Cd19 Protein, MYC/DDK-tagged

• Cat.No.: Cd19-828M
• Product Overview: Purified recombinant protein of full-length mouse CD19 antigen (Cd19), with C-terminal MYC/DDK tag, was expressed in HEK293T cells.

Specification

• Description: Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
• Source: HEK293T
• Species: Mouse
• Tag: Myc&DDK
• Molecular Mass: 60.6 kDa
• Purity: >80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade after receiving vials.
• Concentration: >50 µg/mL as determined by microplate BCA method
• Storage Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.

Gene Information

• Gene Name: Cd19 CD19 antigen [ Mus musculus (house mouse) ]
• Official Symbol: Cd19
• Synonyms: Cd19; CD19 antigen; AW495831; B-lymphocyte antigen CD19; differentiation antigen CD19
• Gene ID: 12478
• mRNA Refseq: NM_009844.
• Protein Refseq: NP_033974
• UniProt ID: P25918

Reviews

01/02/2023

The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

08/18/2022

This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

06/29/2016

Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

Q&As

How does CAR-T cell therapy work to combat CD19-expressing cancers?

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction?

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19?

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target?

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers?

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.